Search results
Results from the WOW.Com Content Network
Exemestane, sold under the brand name Aromasin among others, is a medication used to treat breast cancer. It is a member of the class of antiestrogens known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers have estrogen receptors (ERs), and are called ER-positive. They may also be called estrogen-responsive ...
Particular medications can result in MRONJ, a serious but uncommon side effect in certain individuals. Such medications are frequently used to treat diseases that cause bone resorption such as osteoporosis, or to treat cancer. The main groups of drugs involved are anti-resorptive drugs, and anti-angiogenic drugs.
Potentiates CNS sedatives, [3] chronic use might cause a reversible dry skin condition. [18] Khat: qat Catha edulis: Chronic liver dysfunction [3] [19] Kratom: Mitragyna speciosa: Hepatotoxicity [20] [19] Liquorice root Glycyrrhiza glabra: Hypokalemia, hypertension, arrhythmias, edema [5] Lobelia: asthma weed, pukeweed, vomit wort Lobelia inflata
Commonly prescribed thyroid drug levothyroxine was linked with bone mass and bone density loss in a cohort of older adults in a recent study. ... This in turn causes the thyroid to produce T3 and ...
Ovarian stimulation with the aromatase inhibitor letrozole has been proposed for ovulation induction in order to treat unexplained female infertility. In a multi-center study funded by the National Institute of Child Health and Development, ovarian stimulation with letrozole resulted in a significantly lower frequency of multiple gestation (i.e., twins or triplets) but also a lower frequency ...
Osteoporosis can affect nearly 1 in 3 women and the bone loss is the most rapid within the first 2–3 years after menopause. This can be prevented by menopause hormone therapy or MHT, which is meant to prevent bone loss and the degradation of the bone microarchitecture and is noted to reduce the risk of fractures in bones by 20-30%.
“People with malabsorption in their stomach or intestines, such as patients after weight loss surgery or patients with gastrointestinal issues, need robust vitamin supplementation to maintain ...
The bone loss that occurs with androgen deprivation therapy in men is similar to that which occurs in postmenopausal women. [36] Although androgen deprivation therapy is known to cause osteoporosis, it is thought that CPA may have a lower risk of osteoporosis than GnRH modulators or orchiectomy. [40]